)
Lavipharm (LAVI) investor relations material
Lavipharm Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
FY 2025 sales before rebate & clawback reached €70.03mn, up 14.8% year-over-year, with net income at €5.99mn, down due to a prior year deferred tax asset recognition; excluding this, net profit grew 123.2%.
Adjusted EBITDA rose 48.9% to €15.47mn, reflecting strong operational performance.
Major strategic moves included the cessation of wholesale/logistics, launch of medical cannabis, and acquisition of Durogesic rights.
Leadership credits disciplined execution and employee commitment for performance, emphasizing readiness for accelerated growth and long-term value creation.
Financial highlights
Sales after rebate & clawback were €62.58mn, up 18.2% year-over-year.
Gross profit increased 20.8% to €30.31mn; EBIT rose 68.8% to €9.35mn.
Net result from continued operations was €5.1mn, down 41.7% year-over-year.
Free cash flow turned positive at €2.0mn, compared to -€5.0mn in 2024.
Net debt decreased to €26.57mn from €28.23mn at year-end 2024.
Outlook and guidance
Durogesic acquisition projected to increase annual revenue by 60% and expand EBITDA margin from 22% to 31%.
Commercialization of new products and international expansion expected to drive future growth.
Management highlights strong foundations and clear strategy, positioning for accelerated growth and long-term value creation.
- Net profit after tax surged to €7.7m on stable sales and deferred tax asset recognition.LAVI
Q2 20246 Jul 2026 - After-tax profit soared 338.6% on strong sales and a deferred tax asset recognition.LAVI
Q3 20246 Jul 2026 - Net profit surged 380% on strong sales, strategic deals, and deferred tax gains.LAVI
Q4 20246 Jul 2026 - Sales and EBITDA up, net profit down on tax effect; strong H2 growth expected.LAVI
Q2 20256 Jul 2026 - EBITDA and net profit surged, led by domestic sales, despite a temporary export decline.LAVI
Q1 20256 Jul 2026 - Adjusted EBITDA up 11.2% and domestic prescription sales surged, with Q4 rebound expected.LAVI
Q3 20256 Jul 2026
Next Lavipharm earnings date
Next Lavipharm earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)